{"id":"NCT01753362","sponsor":"University at Buffalo","briefTitle":"Liraglutide In Overweight Patients With Type 1 Diabetes","officialTitle":"LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2017-12","completion":"2018-02","firstPosted":"2012-12-20","resultsPosted":"2019-12-17","lastUpdate":"2019-12-17"},"enrollment":84,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"placebo","type":"PLACEBO_COMPARATOR"},{"label":"liraglutide","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin.","primaryOutcome":{"measure":"HbA1c","timeFrame":"26 weeks","effectByArm":[{"arm":"Placebo","deltaMin":7.77,"sd":0.83},{"arm":"Liraglutide","deltaMin":7.94,"sd":1.05}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":[]}}